EURICAN L

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

LEPTOSPIRA CANICOLA INACTIVATED, LEPTOSPIRA ICTEROHAEMORRHAGIAE INACTIVATED

Commercializzato da:

Merial Animal Health Limited

Codice ATC:

QI07AB01

INN (Nome Internazionale):

LEPTOSPIRA CANICOLA INACTIVATED, LEPTOSPIRA ICTEROHAEMORRHAGIAE INACTIVATED

Dosaggio:

%v/v

Forma farmaceutica:

Suspension for Injection

Tipo di ricetta:

POM

Gruppo terapeutico:

Canine

Area terapeutica:

Leptospira vaccine

Indicazioni terapeutiche:

Immunological - Inactivated vaccine

Stato dell'autorizzazione:

Authorised

Data dell'autorizzazione:

2004-11-05

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican L
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Inactivated_ Leptospira canicola................................._ } >
80% protection*
Inactivated_ Leptospira icterohaemorrhagiae............._ }
Excipient.....................................................................
qs 1 dose of 1 ml
*According to Ph. Eur. hamster potency test
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Suspension for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs from 8 weeks of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs:
Active immunisation against
_Leptospira canicola_ and_ Leptospira icterohaemorrhagiae_ to prevent
mortality and to
reduce clinical symptoms of Leptospira infections caused by these
agents.
Onset of immunity: 14 days after primary vaccination.
The duration of immunity is one year.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
(I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
Vaccinate only healthy animals
(II) SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
MEDICINAL PRODUCT TO THE ANIMALS:
In the case of accidental self-injection, wash the area immediately
with water.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_3_
_1_
_/_
_0_
_3_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_4_
_0_
_6_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.6 ADVERSE REACTIONS